Site icon Patricia Prijatel

Bisphosphonate may benefit metastatic hormone negative breast cancers

According to research in the open-access journal,  BMC Cancer, patients with hormone-negative cancer with bone metastases may  benefit from bisphosphonate (BP) treatment.  Of the 317 patients followed, 230 (72.6%) had hormone positive breast cancer and 87 patients (27.4%) had hormone negative.  

Patients with hormone-positive breast cancer showed no benefit from BP.  Those with hormone-negative,  however, showed what researchers called “significant prolonged survival” from the drug. Disease-free survival was more than two years, with fewer than three metastatic sites.  Patients received an average of 17.7 cycles of BP.

Download a PDF of the research here.
Exit mobile version